Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for ...

CMS often withholds coverage for reimbursement, disrupting the natural flow of the market and hindering access to proven ...

Health and Human Services Secretary Robert F. Kennedy Jr said that President Donald Trump calls him up “three or four times a week” to hound him with the same question. At such a critical moment in US ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Rep. Mark Amodei, a Republican, called President Trump's budget bill a balancing act that reins in excessive Medicaid spending.

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.